Tempus AI (TEM) announced it has acquired Deep 6 AI. Deep 6 AI enables healthcare organizations to de-risk clinical trials, accelerate recruitment, and generate real-world evidence. Its AI-powered software matches patients to clinical trials by mining real-time structured and unstructured electronic medical record data across a broad ecosystem, which includes academic medical centers, National Cancer Institute-Designated Cancer Centers, and NCI Community Oncology Research Programs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Cathie Wood Capitalizes on Pullback in Tempus AI to Buy Additional Stock Worth $14.4M
- Cathie Wood’s ARK Investment bought 271K shares of Tempus AI today
- Tempus AI price target raised to $60 from $50 at Morgan Stanley
- Tempus AI’s Strong Performance and Strategic Growth Justify Buy Rating
- Tempus AI price target lowered to $55 from $70 at Piper Sandler
Questions or Comments about the article? Write to editor@tipranks.com